Profile data is unavailable for this security.
About the company
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
- Revenue in USD (TTM)0.00
- Net income in USD-123.44m
- Incorporated2023
- Employees33.00
- LocationenGene Holdings Inc4868 Rue Levy, Suite 220SAINT-LAURENT H4R 2P1CanadaCAN
- Phone+1 (514) 332-4888
- Websitehttps://engene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AC Immune SA | 17.69m | -69.13m | 316.61m | 133.00 | -- | 2.25 | -- | 17.89 | -0.7332 | -0.7332 | 0.1911 | 1.42 | 0.0787 | -- | 28.76 | 133,041.40 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Tango Therapeutics Inc | 43.38m | -123.40m | 316.88m | 140.00 | -- | 1.38 | -- | 7.30 | -1.15 | -1.15 | 0.4041 | 2.13 | 0.1112 | -- | -- | 309,885.70 | -31.62 | -- | -35.28 | -- | -- | -- | -284.43 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 318.40m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Rezolute Inc | 0.00 | -68.46m | 323.32m | 59.00 | -- | 2.46 | -- | -- | -1.33 | -1.33 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -53.39 | -50.36 | -56.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.87m | 328.01m | 10.00 | -- | 3.34 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -50.53m | 330.10m | 57.00 | -- | 1.26 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Codexis Inc | 64.45m | -62.09m | 332.02m | 174.00 | -- | 4.52 | -- | 5.15 | -0.878 | -0.878 | 0.9149 | 0.902 | 0.4259 | 7.03 | 3.62 | 370,379.30 | -41.03 | -17.13 | -54.21 | -20.23 | 75.96 | 77.29 | -96.35 | -37.04 | 3.15 | -- | 0.2806 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| iTeos Therapeutics Inc | 35.00m | -108.14m | 338.56m | 157.00 | -- | 0.51 | -- | 9.67 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 349.30m | 33.00 | -- | 1.52 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| Lyell Immunopharma Inc | 54.00k | -210.26m | 358.79m | 224.00 | -- | 0.5512 | -- | 6,644.33 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 359.00m | 304.00 | -- | 2.36 | -- | 2.12 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| XOMA Royalty Corp | 15.24m | -25.10m | 362.49m | 13.00 | -- | 3.61 | -- | 23.79 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Jasper Therapeutics Inc | 0.00 | -62.44m | 370.53m | 45.00 | -- | 3.69 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -144.32m | 372.89m | 186.00 | -- | 1.93 | -- | -- | -2.19 | -2.19 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -52.83 | -40.85 | -57.18 | -44.48 | -- | -- | -- | -- | -- | -- | 0.1337 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Northwest Biotherapeutics Inc | 1.65m | -75.55m | 380.59m | 25.00 | -- | -- | -- | 231.36 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Data as of Nov 08 2024. Currency figures normalised to enGene Holdings Inc's reporting currency: US Dollar USD
32.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 30 Jun 2024 | 3.30m | 7.46% |
| BVF Partners LPas of 30 Jun 2024 | 2.25m | 5.09% |
| Deep Track Capital LPas of 30 Jun 2024 | 2.25m | 5.09% |
| Logos Global Management LPas of 30 Jun 2024 | 1.20m | 2.71% |
| Cormorant Asset Management LPas of 30 Jun 2024 | 1.00m | 2.26% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 1.00m | 2.26% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 800.03k | 1.81% |
| Soleus Capital Management LP (Investment Management)as of 30 Jun 2024 | 800.00k | 1.81% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 800.00k | 1.81% |
| Marshall Wace LLPas of 30 Jun 2024 | 764.65k | 1.73% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
